AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38283394 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative intravenous tranexamic acid (TXA)
Number of subjects: 0
Study 38283394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38283573 — intervention group
Group type: EXPERIMENTAL
Intervention: Portico valve (size 23, 25, 27, or 29 mm) using first-generation delivery system (DS)
Number of subjects: 1001
Study 38283573 — intervention group
Group type: EXPERIMENTAL
Intervention: Portico valve (size 23, 25, 27, or 29 mm) using second-generation (FlexNav) DS
Number of subjects: 1001
Study 38283573 — intervention group
Group type: EXPERIMENTAL
Intervention: Portico valve (size 23, 25, 27, or 29 mm)
Number of subjects: 1001
Study 38283689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine
Number of subjects: 0
Study 38283689 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (control)
Number of subjects: 0
Study 38284238 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduction system pacing (CSP)
Number of subjects: 75
Study 38284238 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical pacing (RVAP)
Number of subjects: 75
Study 38284286 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 W power setting
Number of subjects: 46
Study 38284286 — intervention group
Group type: COMPARATOR
Intervention: 50 W power setting
Number of subjects: 46
Study 38284396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle parental touch intervention during painful procedures
Number of subjects: 106
Study 38284396 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the Petal trial
Number of subjects: 106
Study 38284415 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aids
Number of subjects: 107698
Study 38284768 — intervention group
Group type: EXPERIMENTAL
Intervention: MINS (Myocardial Injury after Noncardiac Surgery) defined as TnI level >59 ng/L
Number of subjects: 341
Study 38284768 — intervention group
Group type: COMPARATOR
Intervention: Patients without MINS
Number of subjects: 341
Study 38284768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic TnI changes
Number of subjects: 341
Study 38284925 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based contingency management intervention
Number of subjects: 0
Study 38284925 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38285028 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 50
Study 38285028 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Number of subjects: 50
Study 38285051 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative-AKI
Number of subjects: 9510
Study 38285051 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of early postoperative-AKI
Number of subjects: 9510
Study 38285051 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of early postoperative-AKI
Number of subjects: 9510
Study 38285051 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pre-existing CKD
Number of subjects: 9510
Study 38285051 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD and early AKI
Number of subjects: 9510
Study 38285168 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stitch with a longterm resorbable, elastic suture (poly-4-hydroxybutyrate, [p-4OHB]) aiming at a 6:1 SL/WL-ratio
Number of subjects: 351
Study 38285175 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory sinus arrhythmia (RSA) reactivity and resting RSA as physiological markers
Number of subjects: 0
Study 38285235 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 58741 (1971-1978)
Number of subjects: 890
Study 38285235 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 58831/2
Number of subjects: 890
Study 38285235 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial 58881
Number of subjects: 890
Study 38285244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological ascorbate (intravenous delivery reaching plasma concentrations ≈ 20 mM)
Number of subjects: 55
Study 38285244 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin receptor expression
Number of subjects: 55
Study 38285244 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Susceptibility Mapping (QSM) measures
Number of subjects: 55
Study 38285244 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic iron metabolic markers
Number of subjects: 55
Study 38285245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reserve, depressive symptoms, obesity, and change in employment status
Number of subjects: 426
Study 38285445 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose nonavalent HPV vaccine administered 6 months apart
Number of subjects: 225
Study 38285445 — intervention group
Group type: COMPARATOR
Intervention: 3-dose HPV vaccine regimen administered to historical controls
Number of subjects: 225
Study 38285447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime Bracing (NB)
Number of subjects: 135
Study 38285447 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoliosis-Specific Exercise (SSE)
Number of subjects: 135
Study 38285447 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA) - Control
Number of subjects: 135
Study 38285447 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 135
Study 38285446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (20 mg, followed by 10 mg every 5 minutes)
Number of subjects: 251
Study 38285446 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine sulfate (2 or 3 mg every 5 minutes)
Number of subjects: 251
Study 38285446 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 251
Study 38285446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 251
Study 38285475 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38285502 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote diabetes self-management education (DSME) program including live video education classes, individualized physical activity prescription and counseling, and continuous glucose and wearable physical activity monitoring.
Number of subjects: 10
Study 38285502 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote DSME program with Fitbit Inspire 2 for physical activity assessment and estimated glycated hemoglobin (HbA1c) monitoring.
Number of subjects: 10
Study 38285565 — intervention group
Group type: EXPERIMENTAL
Intervention: Committing to Choose Wisely behavioral economic intervention
Number of subjects: 8030
Study 38285565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8030
Study 38286086 — intervention group
Group type: EXPERIMENTAL
Intervention: CatboostClassifier
Number of subjects: 11201
Study 38286086 — intervention group
Group type: EXPERIMENTAL
Intervention: RandomForestClassifier
Number of subjects: 11201
Study 38286086 — intervention group
Group type: COMPARATOR
Intervention: Logistic Regression
Number of subjects: 11201
Study 38286086 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 11201
Study 38286177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine (QIV-HD)
Number of subjects: 12477
Study 38286223 — intervention group
Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit mind-body activity program
Number of subjects: 87
Study 38286223 — intervention group
Group type: COMPARATOR
Intervention: Healthy Living for Pain (educational comparison)
Number of subjects: 87
Study 38286244 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational activations
Number of subjects: 40
Study 38286244 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal activations
Number of subjects: 40
Study 38286244 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of left atrium occupied by LVZs
Number of subjects: 40
Study 38286244 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy atrium with ≤15% LVZs
Number of subjects: 40
Study 38286244 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational activations in LVZs
Number of subjects: 40
Study 38286244 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of LVZ within 12 mm of focal activation
Number of subjects: 40
Study 38286482 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase (18 mg + 18 mg)
Number of subjects: 1412
Study 38286482 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 1412
Study 38286484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg tenecteplase
Number of subjects: 86
Study 38286484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.32 mg/kg tenecteplase
Number of subjects: 86
Study 38286485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 6412
Study 38286485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 6412
Study 38286618 — intervention group
Group type: EXPERIMENTAL
Intervention: AtoOxy (80/5 mg)
Number of subjects: 19
Study 38286618 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 19
Study 38286618 — intervention group
Group type: EXPERIMENTAL
Intervention: AtoOxy-plus-acetazolamide
Number of subjects: 19
Study 38286618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 38286619 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-led COPD care
Number of subjects: 1242
Study 38286619 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1242
Study 38286683 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cyclic enteral nutrition administered over 10 hours
Number of subjects: 318
Study 38286683 — intervention group
Group type: COMPARATOR
Intervention: Standard continuous enteral nutrition
Number of subjects: 318
Study 38286683 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cyclic enteral nutrition
Number of subjects: 318
Study 38286685 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused art therapy (TFAT) intervention for 10 weeks
Number of subjects: 30
Study 38286685 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (control)
Number of subjects: 30
Study 38286686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy plus compression therapy for 6 weeks after discharge from hospital
Number of subjects: 208
Study 38286686 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208
Study 38286689 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based bimodal lifestyle programme
Number of subjects: 0
Study 38286691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling treatment for fever control within the first 48 hours of septic shock
Number of subjects: 820
Study 38286691 — intervention group
Group type: COMPARATOR
Intervention: No cooling treatment for fever control within the first 48 hours of septic shock
Number of subjects: 820
Study 38286691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling treatment for fever control
Number of subjects: 820
Study 38286691 — intervention group
Group type: COMPARATOR
Intervention: No cooling treatment for fever control
Number of subjects: 820
Study 38286705 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-Movement Desensitisation and Reprocessing (EMDR)
Number of subjects: 0
Study 38286705 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38286704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 6004
Study 38286736 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliopsoas plane block (10 mL 0.75% ropivacaine with 1:200 000 epinephrine)
Number of subjects: 56
Study 38286736 — intervention group
Group type: COMPARATOR
Intervention: Sham block (10 mL normal saline)
Number of subjects: 56
Study 38286736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 38286884 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy (AT)
Number of subjects: 317
Study 38286884 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX as Adjuvant Therapy
Number of subjects: 317
Study 38286884 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy (AT) Delay
Number of subjects: 317
Study 38286916 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for sleep enhancement (two sessions)
Number of subjects: 181
Study 38286916 — intervention group
Group type: COMPARATOR
Intervention: Routine practices of the hospital (control group)
Number of subjects: 181
Study 38286961 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 380
Study 38287068 — intervention group
Group type: EXPERIMENTAL
Intervention: ChulaCov19 50 µg
Number of subjects: 150
Study 38287068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 38287179 — intervention group
Group type: EXPERIMENTAL
Intervention: Gartisertib (250 mg QD) in cohort A2
Number of subjects: 97
Study 38287179 — intervention group
Group type: EXPERIMENTAL
Intervention: Gartisertib + Carboplatin in cohort B1
Number of subjects: 97
Study 38287179 — intervention group
Group type: EXPERIMENTAL
Intervention: Gartisertib (general)
Number of subjects: 97
Study 38287253 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) prevalence defined as serum ferritin < 100 µg/L and/or transferrin saturation coefficient (TSAT) < 20%
Number of subjects: 888
Study 38287253 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of more than three comorbidities
Number of subjects: 888
Study 38287253 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP ≥ 12 mg/L
Number of subjects: 888
Study 38287253 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment that may influence ID/anemia
Number of subjects: 888
Study 38287253 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPB scores
Number of subjects: 888
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified source of infection
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected source of infection
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Household members as source of infection
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended family as source of infection
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Work colleagues as source of infection
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends as source of infection
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple/other sources as infection source
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor settings for transmission events
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged encounters for transmission events
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic source case for transmission events
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask usage during transmission events
Number of subjects: 584846
Study 38287286 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with not knowing the source of infection
Number of subjects: 584846
Study 38287303 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 168
Study 38287303 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 168
Study 38287335 — intervention group
Group type: EXPERIMENTAL
Intervention: ENABLE-SG (telehealth model)
Number of subjects: 300
Study 38287335 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 300
Study 38287335 — intervention group
Group type: COMPARATOR
Intervention: Delayed ENABLE-SG (control)
Number of subjects: 300
Study 38287346 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide therapy (RNT) targeted against prostate-specific membrane antigen (PSMA)
Number of subjects: 0
Study 38287346 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 38287349 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol, probiotics, and additional micronutrients
Number of subjects: 576
Study 38287349 — intervention group
Group type: COMPARATOR
Intervention: Standard micronutrient supplement
Number of subjects: 576
Study 38287417 — intervention group
Group type: EXPERIMENTAL
Intervention: Active manual soft tissue mobilisation of the lumbar spine (n=11)
Number of subjects: 24
Study 38287417 — intervention group
Group type: COMPARATOR
Intervention: Control intervention: light touch over the thoracic region with deep breathing exercises (n=13)
Number of subjects: 24
Study 38287417 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome assessors for active group
Number of subjects: 24
Study 38287417 — intervention group
Group type: COMPARATOR
Intervention: Outcome assessors for control group
Number of subjects: 24
Study 38287424 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase-based training
Number of subjects: 120
Study 38287424 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase-based training
Number of subjects: 120
Study 38287424 — intervention group
Group type: COMPARATOR
Intervention: Regular training during menstrual cycle
Number of subjects: 120
Study 38287431 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (6-month duration)
Number of subjects: 27
Study 38287611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg bodyweight intravenously followed by weekly subcutaneous injections of 162 mg) after 500 mg methylprednisolone intravenously for 3 days.
Number of subjects: 18
Study 38287700 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding Calcium (Ca)
Number of subjects: 0
Study 38287923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention including care management, cognitive behavioral therapy elements, and psychopharmacology addressing PTSD symptoms.
Number of subjects: 350
Study 38287923 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care control
Number of subjects: 350
Study 38288052 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated risk score for in-hospital mortality
Number of subjects: 2229
Study 38288052 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated risk score for composite outcome
Number of subjects: 2229
Study 38288052 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated risk score for late mortality
Number of subjects: 2229
Study 38288052 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated risk score predictive of in-hospital mortality
Number of subjects: 2229
Study 38288052 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated risk score predictive of composite outcome
Number of subjects: 2229
Study 38288052 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated risk score predictive of late mortality excluding hospital deaths
Number of subjects: 2229
Study 38288082 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication algorithm for respiratory-related hospitalisation
Number of subjects: 0
Study 38288117 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-cycle induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy (cCRT) and consolidation toripalimab
Number of subjects: 50
Study 38288117 — intervention group
Group type: COMPARATOR
Intervention: 2-cycle induction chemotherapy followed by concurrent chemoradiotherapy (cCRT) and consolidation toripalimab
Number of subjects: 50
Study 38288393 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital bracket positioning using 3D Maestro® software
Number of subjects: 30
Study 38288393 — intervention group
Group type: COMPARATOR
Intervention: Manual bracket positioning using Ray Set® device
Number of subjects: 30
Study 38288393 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM jigs
Number of subjects: 30
Study 38288393 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed indirect bonding trays (IBT)
Number of subjects: 30
Study 38288393 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer vacuum-formed thermoplastic IBT
Number of subjects: 30
Study 38288731 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum urate responders (achieved serum urate < 6 mg/dL)
Number of subjects: 588
Study 38288731 — intervention group
Group type: COMPARATOR
Intervention: Serum urate non-responders (did not achieve serum urate < 6 mg/dL)
Number of subjects: 588
Study 38288731 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum urate responders
Number of subjects: 588
Study 38288731 — intervention group
Group type: COMPARATOR
Intervention: Serum urate non-responders
Number of subjects: 588
Study 38288741 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 1 × 10^6 allogeneic bone marrow-derived mesenchymal stromal cells
Number of subjects: 20
Study 38288802 — intervention group
Group type: EXPERIMENTAL
Intervention: Keytruda (pembrolizumab)
Number of subjects: 0
Study 38288802 — intervention group
Group type: EXPERIMENTAL
Intervention: Imfinzi (durvalumab)
Number of subjects: 0
Study 38288802 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38288862 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet regimen (cobimetinib 60 mg daily for days 1-21 + niraparib 200 mg daily for days 1-28)
Number of subjects: 74
Study 38288862 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet regimen (cobimetinib 60 mg daily for days 1-21 + niraparib 200 mg daily for days 1-28 + atezolizumab 840 mg on days 1 and 15)
Number of subjects: 74
Study 38288892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W
Number of subjects: 266
Study 38288892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W
Number of subjects: 266
Study 38288892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 38288922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (adalimumab 40 mg subcutaneously every other week + methotrexate 15 mg weekly)
Number of subjects: 245
Study 38288922 — intervention group
Group type: COMPARATOR
Intervention: Escalated methotrexate (up to 25 mg weekly)
Number of subjects: 245